Merck MRK
today announced the first-time presentation of findings investigating
the use of KEYTRUDA® (pembrolizumab), the company's anti-PD-1
therapy, as a monotherapy in patients with advanced unresectable
nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose
tumors express PD-L1 (≥1% of cells in tumor nests or PD-L1+ bands in
stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an
overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent
(95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with
KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu,
National Taiwan University Hospital, at the European Cancer Congress
(ECC) in Vienna (Abstract #2801).
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in